NCT04735978View on ClinicalTrials.gov

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

RP3

Genetically modified HSV-1

BIOLOGICAL

Nivolumab

anti-PD1 monoclonal antibody

Trial Locations (13)

11527

University of Athens, Athens

12462

University General Hospital Attikon, Athens

15232

UPMC Hillman Cancer Center, Pittsburgh

28050

START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3, Madrid

46010

Hospital Clinico Universitario de Valencia, Valencia

52242

University of Iowa, Iowa City

77030

MD Anderson Cancer Center, Houston

94805

Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy, Villejuif

08035

Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital), Barcelona

08036

Hospital Clinic Barcelona, Barcelona

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

OX3 9DU

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Replimune Inc.

INDUSTRY

NCT04735978 - Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | Biotech Hunter | Biotech Hunter